Gabapentin Capsule
Product Images NDC 55154-0580

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55154-0580). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A text panel showing a formula for calculating creatinine clearance (CLCr). The formula involves age, weight, serum creatinine, and a factor for female patients. It appears to be a clinical calculation related to renal function.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure of gabapentin showing a cyclohexane ring with attached CH2NH2 and CH2CO2H groups.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks labeled from baseline to 8, with annotations for a 4-week dose titration period and a 4-week fixed dose period. The y-axis ranges from 0 to 10 for mean pain score. Gabapentin shows a decreasing pain trend, while placebo remains relatively constant.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over seven weeks for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including baseline, and the y-axis shows the mean pain score from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating pain score trends for each group over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for gabapentin groups compared to placebo.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot showing the relationship between daily dose (mg) on the x-axis and percentage difference on the y-axis for three studies labeled a, b, and c. Study a is marked with solid black squares, study b with gray squares, and study c with white squares indicating differences at various doses ranging from approximately 600 mg to 1800 mg daily.*

FDA Label Image

100mg Bag Label (999f3685 2eac 467e Bed2 1d0c36aaf0ed 02)

FDA Label Image

300mg Bag Label (999f3685 2eac 467e Bed2 1d0c36aaf0ed 01)

FDA Label Image

400mg Bag Label (999f3685 2eac 467e Bed2 1d0c36aaf0ed 00)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.